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Pancreatic ductal adenocarcinoma (PDAC) patients have a 5-year survival rate of only 8%
largely due to late diagnosis and insufficient therapeutic options. Neutrophils are among the
most abundant immune cell type within the PDAC tumor microenvironment (TME), and are
associated with a poor clinical prognosis. However, despite recent advances in understanding
neutrophil biology in cancer, therapies targeting tumor-associated neutrophils are lacking.
Here, we demonstrate, using pre-clinical mouse models of PDAC, that lorlatinib attenuates
PDAC progression by suppressing neutrophil development and mobilization, and by mod-
ulating tumor-promoting neutrophil functions within the TME. When combined, lorlatinib also
improves the response to anti-PD-1 blockade resulting in more activated CD8+ T cells in
PDAC tumors. In summary, this study identifies an effect of lorlatinib in modulating tumor-
associated neutrophils, and demonstrates the potential of lorlatinib to treat PDAC.
https://doi.org/10.1038/s41467-021-23731-7 OPEN
1 Biotech Research and Innovation Centre (BRIC), University of Copenhagen (UCPH), Copenhagen, Denmark. 2 CRUK Beatson Institute, Garscube Estate,
Glasgow, UK. 3 Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, NY, USA. 4 Lustgarten Pancreatic Cancer Research Laboratory, Cold Spring
Harbor, New York, NY, USA. 5Department of Microbiology and Molecular Genetics, University of California Davis, Davis, CA, USA. 6 Institute of Cancer
Sciences, University of Glasgow, Garscube Estate, Glasgow, UK. 7These authors contributed equally: Sebastian R. Nielsen, Jan E. Strøbech. ✉email: sebastian.
nielsen@bric.ku.dk; janine.erler@bric.ku.dk









Pancreatic ductal adenocarcinoma (PDAC) has a dismalsurvival prognosis with only 8% of patients surviving formore than 5 years, largely due to late diagnosis and insuf-
ficient therapeutic options1. PDAC tumors and metastatic lesions
are both characterized by excessive deposition of the extracellular
matrix (ECM), and a tumor microenvironment (TME) contain-
ing fibroblasts and different immune cells2–4. Macrophages and
neutrophils, the most abundant immune cells within the PDAC
TME, are associated with a poor clinical prognosis due to their
immunosuppressive properties and roles in mediating therapeutic
resistance5–8. While several strategies that target macrophages are
currently being evaluated in clinical trials9,10, few therapies
that target the function of tumor-associated neutrophils are
available11. In the metastatic setting, neutrophils (as well as other
cell types) are responsible for the establishment of a hospitable
niche that promotes the growth of disseminated PDAC cells12,13.
In addition, a high neutrophil-to-lymphocyte ratio in patient
blood samples is a prognostic marker for decreased postoperative
survival in PDAC patients14. Neutrophils are produced in
the bone marrow (BM) from hematopoietic progenitor cells and
are recruited to tumors by tumor cell-derived cytokines and
chemokines15, where they then promote tumor growth through
the production of cytokines and secretion of ECM-modulating
enzymes15. In addition, neutrophils support the survival of cir-
culating tumor cells and promote the establishment of metastatic
lesions by enhancing cancer stem cell features of metastasis-
initiating cells and by suppressing CD8+ T-cell and NK cell
cytotoxicity at the metastatic site16–19. However, neutrophils with
anti-tumorigenic properties have also been described20,21, sug-
gesting that the modulation of the recruitment and/or specific
functions of tumor-associated neutrophils could be an effective
therapeutic strategy for cancer patients.
Changes to the TME stimulate intracellular signaling pathways
that enable cells to respond accordingly. One major mechanism
of signaling is protein phosphorylation mediated by protein
kinases. There are 518 protein kinases in the human body22
and many anticancer agents target kinase signaling23. Lorlatinib
(PF-06463922) is an FDA-approved, third-generation, ATP-
competitive small-molecule tyrosine kinase inhibitor that shows
promising results in pre-clinical tests and clinical trials in patients
suffering from non-small-cell lung cancer with genetic rearran-
gements of anaplastic lymphoma kinase (ALK) or ROS124,25.
Lorlatinib can also potently inhibit other tyrosine kinases, such as
the non-receptor tyrosine kinase FES26.
Here, our goal was to uncover neutrophil targeting therapies
through analysis of tumor-activated kinase signaling in neu-
trophils. We identify the non-receptor tyrosine kinase FES as a
possible target to suppress neutrophils and prevent PDAC pro-
gression. In pre-clinical mouse models of PDAC, we discover that
lorlatinib indirectly suppresses the growth of PDAC at primary
and metastatic sites by modulating neutrophil development and
recruitment from the BM and by suppressing neutrophil-induced
tumor growth within the TME. Finally, we find that lorlatinib
improves the response to anti-PD-1 blockade in PDAC tumors.
Results
PDAC cells activate FES kinase in neutrophils, which can be
inhibited by lorlatinib. To determine potential signaling path-
ways in neutrophils that are activated in PDAC and might serve
as therapeutic targets to modulate neutrophil function in cancer,
we used a commercially available kinase profiling array to
monitor the phosphorylation of 196 tyrosine bait peptides. We
isolated the BM from healthy mice, enriched for neutrophils by
magnetic depletion (Supplementary Fig. 1a), and then stimulated
the cells with conditioned medium from the pancreatic cancer cell
line KPC mT4 (KPC-CM) for 1 h and used the neutrophil protein
lysate for kinase profiling analysis. Based on the peptide phos-
phorylation levels, the activity of corresponding kinases was
predicted by a group-based prediction system27,28. We found that
the non-receptor tyrosine kinases FES, BTK, JAK1, EphA8, and
EphB1 were activated in neutrophils stimulated with KPC-CM
(Fig. 1a). Inhibition of JAK or BTK signaling has previously
been demonstrated in pre-clinical PDAC models29–31. We also
isolated bone marrow neutrophils from the KPC mouse model
(KrasLSL-G12D/+;Trp53LSL-R172H/+;Pdx1–Cre) with pancreatic
tumors and demonstrated that FES was among the group of
kinases with significant increased activity compared to neu-
trophils from tumor-free control mice (Supplementary Fig. 1b).
Interestingly, it was recently reported that lorlatinib (PF-
06463922), an FDA-approved inhibitor of ALK, potently inhibits
FES26. To test if lorlatinib could inhibit FES activity in neu-
trophils, we stimulated neutrophils with KPC-CM in the presence
of lorlatinib or vehicle for 1 h and used the profiling array to
determine kinase activity. We found that lorlatinib reduced the
activity of FES based on the phosphorylation pattern of the bait
peptides in the array (Fig. 1b).
FES has been associated with signaling through STAT
proteins32, and both STAT3 and STAT5 play a role in neutrophil
development and homeostasis33–35. Therefore, we hypothesized
that lorlatinib inhibition of FES signaling would result in reduced
phosphorylation of STAT proteins. Indeed, we observed reduced
phosphorylation of STAT5 when we added lorlatinib to
neutrophils stimulated with KPC-CM, whereas no change was
observed in the phosphorylation of STAT3 (Fig. 1c, S2a–e). We
determined that Fes is expressed in CD11b+ -sorted myeloid
cells from an orthotopic PDAC tumor (Supplementary Fig. 1c)
and we further confirmed that Fes is expressed at the highest level
in neutrophils by analyzing Fes expression in neutrophils
(Ly6G+), monocytes (Ly6C+) and macrophages (F4/80+) sorted
from pancreatic tumors from the KPC mouse model (Supple-
mentary Fig. 1d). To determine how lorlatinib modulates
neutrophils we tested neutrophil migration by seeding freshly
isolated BM neutrophils in transwell inserts with KPC-CM as a
chemoattractant in the bottom chamber. We observed that
lorlatinib reduces neutrophil migration in response to KPC-CM
compared to vehicle (Fig. 1d). To explore the influence of
lorlatinib-treated neutrophils on cancer cell growth, we cultured
zsGreen-expressing KPC mT4 cells together with freshly isolated
BM neutrophils in KPC-CM in the presence of lorlatinib or
vehicle. After 2 days of co-culture, we fixed the cells and
quantified the number of zsGreen+ cells. While we did not see
any effect of lorlatinib on the number of zsGreen+ cells without
neutrophils present, we found that lorlatinib reduced the number
of KPC mT4 cells in neutrophil co-cultures compared to vehicle
(Fig. 1e, S1e). We confirmed that lorlatinib does not inhibit the
proliferation of KPC cells using a cell viability assay (Supple-
mentary Fig. 1f). Finally, to confirm that the effect of lorlatinib on
neutrophil function is not caused by directly inducing cell death,
we isolated BM neutrophils and determined their viability in the
presence of lorlatinib after 2 days of cell culture. As reported
previously36, neutrophil viability declines very fast in regular cell
culture medium and was not detectable at day 2. However, we
were able to rescue neutrophil viability when cells were cultured
in either KPC-CM, GM-CSF or G-CSF (Supplementary Fig. 1g).
Importantly, the presence of lorlatinib in either condition did
not reduce neutrophil viability (Supplementary Fig. 1g). Taken
together, these results suggest that PDAC cells induce FES activity
in neutrophils in vitro, and that lorlatinib could be used to target
tumor-associated neutrophils in PDAC.
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Lorlatinib attenuates PDAC growth by suppressing neutrophil
accumulation. Lorlatinib shows promising results in clinical trials
with patients suffering from non-small-cell lung cancer with
genetic rearrangement of ALK or ROS124,25, however, only a very
small percentage of human PDAC patients have detectable ALK
expression37. Based on our results on neutrophils in vitro, we
decided to test whether lorlatinib could inhibit PDAC tumor
growth in vivo. We injected KPC mT4 cells into the pancreas of
healthy syngeneic mice and started the treatment of established
tumors after 14 days with a daily oral dose of lorlatinib (5 mg/kg)
for a further 14 days. Mice were euthanized 28 days after tumor
cell injection and analyzed (Fig. 1f). The weight of PDAC tumors
was significantly reduced in lorlatinib-treated mice compared to
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by IHC staining for markers of proliferation (Ki67) and apoptosis
(cleaved caspase 3), we observed a reduction in proliferation
(Fig. 1h), but no difference in apoptosis (Supplementary Fig. 3b).
PDAC tumors are characterized by excessive deposition of ECM,
which is believed to affect treatment efficacy by limiting drug
delivery, and a high degree of immune cell infiltration3. To
determine whether lorlatinib modulates these aspects of the
PDAC TME, we performed flow cytometry (Supplementary
Fig. 3c–e) and IHC staining to evaluate immune cell composition
and fibrosis, respectively, of tumors from vehicle- or lorlatinib-
treated mice. We did not detect any difference in the percentage
of F4/80+ macrophages, Ly6C+ monocytes, Nk1.1+ NK cells or
CD3+ T cells among CD45+ immune cells in the tumor (Sup-
plementary Fig. 3f). In contrast, we detected a significant increase
in B220+ B cells and a reduction in Ly6G+ neutrophils in
lorlatinib-treated mice (Fig. 1i, Supplementary Fig. 3f). Since B
cells are mainly pro-tumorigenic in PDAC38, we focused on the
effect of lorlatinib on neutrophils. We confirmed by immuno-
fluorescence staining of tumor sections that lorlatinib treatment
reduced the number of neutrophils in PDAC tumors (Fig. 1j).
Next, we analyzed the tumors for fibrosis by IHC. We found that
lorlatinib-treated mice had markedly reduced levels of fibrosis, as
seen by both decreased collagen deposition and reduced numbers
of αSΜΑ+ fibroblasts compared to vehicle-treated mice (Fig. 1k,l).
Combined with our results obtained with neutrophils in vitro,
these data suggest that lorlatinib inhibits PDAC progression by
suppressing neutrophil accumulation and reducing tumor-
associated fibrosis in the TME.
Lorlatinib reduces metastatic growth in the liver. Currently, the
best treatment option for PDAC patients is the surgical removal
of the pancreatic tumor. Unfortunately, by the time PDAC
patients are diagnosed, most (∼80%) present with non-resectable
tumors and/or metastatic disease. Moreover, surgically-resected
patients that relapse with distant hepatic recurrence have a sig-
nificantly reduced median recurrence-free survival compared to
patients with all other recurrence patterns (i.e., local or lung)39,40.
To assess if lorlatinib could suppress the growth of PDAC
metastatic lesions in the liver, we used an experimental liver
metastasis model. We injected KPC mT4 cells into the spleen of
healthy syngeneic mice. In this model, tumor cells drain directly
from the spleen into the liver through the portal circulation and
generate metastases restricted to the liver12. We started treatment
with lorlatinib 7 days after the intrasplenic injection and con-
tinued daily treatment for 14 days, after which metastases were
analyzed (Fig. 2a). We found that the liver weight relative to the
body weight was reduced in mice treated with lorlatinib com-
pared to vehicle-treated mice (Fig. 2b). We further quantified the
size and number of metastatic lesions in the liver and found a
significant decrease in size but not the number of metastatic
lesions in livers of lorlatinib-treated mice (Fig. 2c and S4a), which
leads to a significant reduction in metastatic burden in lorlatinib-
treated mice (Supplementary Fig. 4b). Similar to our results from
the orthotopic model, we evaluated proliferation and apoptosis by
IHC and observed a reduction in proliferative cells in liver
metastases from lorlatinib-treated mice (Fig. 2d), but no differ-
ence in apoptosis (Supplementary Fig. 4c), compared to vehicle-
treated mice. These results suggest, similar to the orthotopic
model, that lorlatinib suppresses the growth of metastatic lesions
in the liver. To assess the composition of immune cells in
lorlatinib-treated metastases, we prepared single-cell suspensions
and performed flow cytometry analysis. We did not detect any
difference in the percentage of F4/80+ macrophages, Ly6C+
monocytes, B220+ B cells, Nk1.1+ NK cells, CD4+ or CD8+
T cells among CD45+ immune cells in the tumor (Supplementary
Fig. 4d). In contrast, we detected a significant reduction in Ly6G+
neutrophils in lorlatinib-treated mice (Fig. 2e). We confirmed by
immunofluorescence staining of tumor sections that lorlatinib
treatment reduced the number of neutrophils in hepatic metas-
tases (Fig. 2f). Metastatic lesions from pancreatic cancer are
characterized by excessive deposition of ECM similar to the
primary tumor site12. Similarly, we found that metastatic lesions
in lorlatinib-treated mice had markedly reduced levels of fibrosis,
as seen by both decreased collagen deposition and reduced
numbers of αSMA+ cells compared with metastatic lesions from
vehicle-treated mice (Fig. 2g, h). To confirm that reduced neu-
trophil influx, fibrosis, and fibroblast accumulation are not simply
due to the presence of smaller metastases in lorlatinib-treated
mice, we analyzed size-matched lesions by IHC staining.
We found that both neutrophil and fibroblast accumulation in
size-matched metastases was reduced in mice treated with lorla-
tinib, whereas the reduction in fibrosis was not significant (Sup-
plementary Fig. 4e). Taken together, these results suggest that
lorlatinib inhibits PDAC tumor growth both at the primary
tumor site and at a secondary site, by suppressing tumor-
associated neutrophils and cancer-associated fibroblasts (CAFs),
the latter possibly as an indirect effect of the inhibition of
neutrophils.
While we cannot exclude a direct effect on tumor cells, our
results suggest that the main effect of lorlatinib is on cells of the
Fig. 1 PDAC cells activate FES kinase signaling in neutrophils, which can be inhibited with lorlatinib to suppress neutrophil accumulation in PDAC
tumors. a, b Volcano plots of the kinase activity prediction in neutrophils stimulated with (a) control or KPC-conditioned medium (KPC-CM) or (b) KPC-
CM for 1 h in the presence of vehicle or 10 µM lorlatinib (data show results from three independent experiments). c Immunoblot analysis of p-STAT5,
STAT5, p-STAT3, and STAT3 in neutrophils stimulated with control or KPC-CM in the presence of vehicle or lorlatinib (immunoblots are representative of
one experiment performed three times). Sample integrity controls are vinculin and tubulin, respectively. Unprocessed scans of immunoblots are shown in
Supplementary Fig. 2. d Transwell migration of neutrophils towards KPC-CM in presence of vehicle (V), 1 μM or 10 μM lorlatinib (n= 3 independent
experiments). e Representative immunofluorescence images of neutrophil/KPC-zsGreen co-cultures in the presence of vehicle or lorlatinib after 2 days of
culture (n= 3 independent experiments). f Orthotopic implantation of KPC mT4 cells into the pancreas. Mice were treated daily with vehicle (V) or 5 mg/kg
lorlatinib (L) for 2 weeks starting 14 days after implantation. g Tumor weight of orthotopic PDAC tumors after treatment with vehicle or 5mg/kg lorlatinib
(n= 12 mice per condition; data are from two independent experiments). h Representative IHC images of Ki67 in tumors from mice treated with vehicle
control or lorlatinib (n= 11 mice, vehicle; n= 6 mice, lorlatinib). Data are from two independent experiments. i Flow cytometry analysis of neutrophils in
PDAC tumors from mice treated with vehicle or lorlatinib (n= 11 mice, vehicle; n= 9 mice, lorlatinib; data are from two experiments).
j–l Representative images of (j) neutrophils (Ly6G+; purple) (n= 10 mice, vehicle; n= 9 mice, lorlatinib), (k) picrosirius red (n= 11 mice, vehicle; n= 10
mice, lorlatinib), and (l) fibroblasts (αSMA+; green) (n= 12 mice, vehicle; n= 10 mice, lorlatinib) in tumors from mice treated with vehicle control or
lorlatinib. Data are from two independent experiments. Scale bars represent 100 µm (h, j–l) or 200 µm (e). Box-and-whisker plot shows the median (line),
mean (plus sign), 25th and 75th percentiles (box), and 5th and 95th percentiles (whiskers); bar graphs represent mean and standard deviation; hypothesis
testing performed using two-way ANOVA with Tukey’s method for multiple comparisons (d, e) or unpaired two-sided Student’s t test (g–l). Source data are
provided as a Source Data file.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-23731-7
4 NATURE COMMUNICATIONS |         (2021) 12:3414 | https://doi.org/10.1038/s41467-021-23731-7 | www.nature.com/naturecommunications
TME. Therefore, we hypothesized that lorlatinib treatment would
be applicable in other cancer types with a heterogenous TME
composition. Given that the liver is a common site of metastasis
for other gastrointestinal cancers such as colorectal cancer (CRC),
we determined if lorlatinib treatment could also inhibit metastatic
progression by CRC cells. To test this, we prepared single-cell
suspensions from small colorectal tumor-derived organoids from
villinCreER Apcfl/flKrasG12D/+Trp53fl/R172HTgfbrIfl/fl (AKPT)
mice41 and injected them directly into the spleen of healthy
syngeneic mice. We started lorlatinib treatment 9 days after the
intrasplenic injections and administered daily treatment for
20 days, after which, we analyzed metastatic burden by IHC
(Fig. 2i). We found that the liver weight relative to the body
weight was reduced in mice treated with lorlatinib compared to
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vehicle-treated mice (Fig. 2j). We further quantified the number
and size of metastatic lesions in the liver, and found a significant
decrease in size of metastatic lesions in livers of lorlatinib-treated
mice, while there was no significant difference in the number
of metastatic lesions (Fig. 2k and S4f). We also evaluated
proliferation and apoptosis by IHC, and observed similar results
as in our previous models (Fig. 2l and S4g). Taken together, these
results suggest that lorlatinib affects the growth of metastatic CRC
lesions. Similar to the results from our PDAC metastasis model,
we found that the CRC metastatic lesions in lorlatinib-treated
mice had a reduced number of neutrophils (Fig. 2m). Finally, we
found reduced levels of fibrosis in CRC metastatic lesions from
lorlatinib-treated mice, as seen by both decreased collagen
deposition and reduced numbers of αSMA+ fibroblasts, compared
with metastatic lesions from vehicle-treated mice (Fig. 2n, o).
Taken together, these results suggest that lorlatinib inhibits tumor
growth both at the primary site and a secondary site, in different
tumor types by modulating neutrophils and the TME.
Lorlatinib targets neutrophils to limit PDAC progression. We
sought to determine if neutrophils support tumor progression in
our orthotopic PDAC model and if lorlatinib targets neutrophils
by comparing neutrophil depletion with lorlatinib treatment. We
implanted KPC mT4 cells into the pancreas of syngeneic mice
and depleted neutrophils by administering an anti-Ly6G antibody
every 3 days over 2 weeks, after which tumors were harvested for
analysis. In addition, we combined neutrophil depletion with
daily lorlatinib treatment to determine the effect of depleting
neutrophils on the efficacy of lorlatinib treatment (Fig. 3a). As
expected, neutrophils were significantly reduced in tumors of
anti-Ly6G-treated animals as determined by flow cytometry
(Fig. 3b) and IHC analysis (Supplementary Fig. 5a). Importantly,
the weight of orthotopic PDAC tumors was significantly reduced
after neutrophil depletion or lorlatinib treatment compared to
mice treated with control IgG and vehicle (Fig. 3c). Interestingly,
there was no increased benefit of depleting neutrophils in com-
bination with lorlatinib treatment compared to either single
treatment (Fig. 3c). Furthermore, we found that neutrophil
depletion reduces proliferation as measured by the decrease of
Ki67+ cells in tumors from neutrophil-depleted mice, but we did
not observe any difference in Ki67+ cells when comparing neu-
trophil depletion with lorlatinib alone or the combination of
neutrophil depletion and lorlatinib (Supplementary Fig. 5b).
Finally, collagen deposition and the accumulation of αSΜΑ+
fibroblasts was also reduced in neutrophil-depleted mice through
anti-Ly6G compared to control IgG and vehicle resulting in
reduced tumor-associated fibrosis. Moreover, we did not observe
further reductions in fibrosis when compared to treatment with
lorlatinib alone or combined neutrophil depletion with lorlatinib
(Supplementary Fig. 5c, d). To assess whether lorlatinib has a
direct inhibitory effect on CAFs, we analyzed two independent
CAF cell lines isolated from PDAC tumors in the KPC mouse
model42, and found no effect of lorlatinib on either CAF pro-
liferation, matrix contraction of collagen I gels with CAFs
embedded, or gene expression of CAF activation markers, Acta2
and Col1a1, when CAFs were stimulated with KPC-CM in the
presence of lorlatinib (Supplementary Fig. 6a–c). These results
suggest that lorlatinib specifically targets neutrophils to suppress
PDAC since we do not see an added effect with lorlatinib in
neutrophil-depleted mice.
Lorlatinib suppresses neutrophil expansion in the BM. Neu-
trophils are produced daily in vast numbers through progressively
differentiated precursors within the BM and are released into
circulation43. A fundamental characteristic of this process is their
release from the BM into the blood circulation and their migration
to sites of inflammation. In cancer, tumor-secreted cytokines sti-
mulate the development and release of neutrophils with an
immunosuppressive and tumor-promoting phenotype into the
circulation44,45. To gain a better understanding of how the pan-
creatic cancer cells modulate neutrophil function, we collected
KPC-CM and analyzed cytokine and chemokine secretion. We
found that KPC cells secrete several cytokines and chemokines,
including CXCL1, G-CSF, and GM-CSF (Supplementary Fig. 7a),
which are known neutrophil regulators15. To determine whether
lorlatinib could modulate the response of neutrophils to these
secreted factors, we investigated the ability of neutrophils to
migrate towards each factor in the presence or absence of lorla-
tinib. We found that CXCL1, G-CSF, and GM-CSF induced
neutrophil migration, however, this effect was abrogated for G-
CSF and GM-CSF in the presence of lorlatinib, whereas lorlatinib
did not affect neutrophil migration in response to CXCL1 (Sup-
plementary Fig. 7b). To determine if reduced neutrophil accu-
mulation in tumors is caused by a systemic effect of lorlatinib
treatment and not just suppression of neutrophil migration into
the tumor, we analyzed peripheral blood from tumor-bearing
vehicle- or lorlatinib-treated mice and found a significant decrease
of neutrophils in blood samples from lorlatinib-treated tumor-
bearing mice (Fig. 3d). Development of neutrophils was recently
described to progress from a proliferative neutrophil precursor
population, termed pre-neutrophils, that gives rise to an inter-
mediate population of immature neutrophils in the BM before
Fig. 2 Lorlatinib treatment attenuates progression of hepatic PDAC and CRC metastases. a Intrasplenic injection of KPC mT4. Mice were treated daily
with vehicle (V) or 5 mg/kg lorlatinib (L) for 2 weeks starting 7 days after implantation. b, c Quantification of hepatic metastatic burden after vehicle or
lorlatinib treatment by (b) liver weight (%) of total body weight and (c) hematoxylin & eosin staining and average size of metastatic lesions (n= 9 mice,
vehicle; n= 11 mice; data are from two independent experiments). d Representative IHC images of Ki67 (n= 9 mice per group). Data are from two
independent experiments. e Flow cytometry analysis of neutrophils (CD11b+ F4/80neg Ly6Cneg Ly6G+) in hepatic metastases from vehicle- or lorlatinib-
treated mice (n= 8 mice, vehicle; n= 10 mice, lorlatinib; data are from two independent experiments). f–h Representative images of (f) neutrophils
(Ly6G+; purple) (n= 8 mice, vehicle; n= 10 mice, lorlatinib), (g) picrosirius red (n= 8 mice, vehicle; n= 9 mice, lorlatinib), and (h) fibroblasts (αSMA+;
green) (n= 8 mice, vehicle; n= 10 mice, lorlatinib) in hepatic metastases from vehicle- and lorlatinib-treated mice. Data are from two independent
experiments. i Intrasplenic injection of CRC organoids from villinCreER Apcfl/fl KrasG12D/+ Trp53fl/R172H TgfbrIfl/fl (AKPT). Mice were treated with vehicle or
5 mg/kg lorlatinib starting 9 days after injection. Hepatic metastatic burden was determined 20 days after the start of treatment. j, k Quantification of
hepatic metastases in mice after intrasplenic injection of CRC organoids and vehicle or lorlatinib treatment by (j) liver weight (%) of total body weight and
(k) representative hematoxylin & eosin staining with quantification of the average metastatic lesion size (n= 5 per group; data are from one experiment).
Black lines show the outline of individual metastatic lesions. l–o Representative IHC and immunofluorescence images of (l) Ki67 (n= 4 mice, vehicle; n= 5
mice, lorlatinib), (m) neutrophils (Ly6G+; green) (n= 5 mice per group), (n) picrosirius red (n= 5 mice per group), and (o) fibroblasts (αSMA+; green)
(n= 5 mice per group) in hepatic metastases from vehicle- and lorlatinib-treated mice. Data are from one experiment. Scale bars represent 5 mm (c, k) or
100 µm (d, f–h, l–o). Box-and-whisker plot shows the median (line), mean (plus sign), 25th and 75th percentiles (box), and 5th and 95th percentiles
(whiskers); hypothesis testing performed using unpaired two-sided Student’s t test (b–o). Source data are provided as a Source Data file.
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differentiating into mature neutrophils46. Pre-neutrophils are
cKit+, whereas immature neutrophils are cKit−Ly6G+CXCR2−
and mature neutrophils are cKit−Ly6G+CXCR2+. Based on our
results, we hypothesized that lorlatinib affects neutrophil devel-
opment in the BM. To evaluate this, we implanted KPC mT4 cells
into the pancreas of healthy mice and started treatment with
lorlatinib after 14 days for a further 2 weeks. We isolated and
prepared single-cell suspensions from the BM and tumors from
lorlatinib-treated mice and analyzed the maturation of neutrophils
by flow cytometry using the markers described above (Supple-
mentary Fig. 8a, b). We found that lorlatinib reduced the number
of mature neutrophils in orthotopic PDAC tumors, while no
significant difference was detected for immature neutrophils in the
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mature neutrophils were reduced in the BM, while numbers of
granulocyte–macrophage progenitors (GMP) and pre-neutrophils
were not changed (Fig. 3f). We noted a higher expression of FES
in neutrophil subsets in both mouse46 and human47 BM (Sup-
plementary Fig. 8c, d). To determine if lorlatinib treatment
reduces granulopoiesis, we evaluated the ability of freshly isolated
BM cells from healthy mice to establish colonies in semi-solid
methylcellulose medium supplemented with recombinant cyto-
kines (SCF, IL-3, and IL-6). We counted established colonies
3 days after BM isolation and observed that lorlatinib reduced the
number of colonies in a dose-dependent manner (Fig. 3g). Based
on our results that lorlatinib does not affect the viability of neu-
trophils isolated from the BM (Supplementary Fig. 1g), we decided
to test if lorlatinib instead inhibits the development of neutrophils.
We isolated BM from healthy mice and seeded the cells in semi-
solid methylcellulose with vehicle or lorlatinib as before. We
included either G-CSF or GM-CSF to promote neutrophil devel-
opment and cultured the cells for 3 days before we analyzed them
by flow cytometry. We found an increased number of colonies
after the addition of G-CSF and GM-CSF, but while lorlatinib was
able to reduce colony formation after the addition of G-CSF at
both 1 and 10 μM, it was only able to reduce colony formation
after addition of GM-CSF at 10 μM (Fig. 3h and S8e). We
observed no difference in GMPs, pre-neutrophils, or mature
neutrophils after treatment with lorlatinib in control or after G-
CSF stimulation, while lorlatinib decreased the number of
immature neutrophils at 10 μM in control and G-CSF cultures
(Fig. 3i, j). The decrease in immature neutrophils was not sig-
nificant for GM-CSF-treated cultures (Supplementary Fig. 8f). Of
note, we did not observe any difference in GMP or neutrophil
subsets in the blood or BM from tumor-free mice treated with
lorlatinib for 14 days (Supplementary Fig. 8g, h). These results
suggest that lorlatinib suppresses tumor-induced granulopoiesis in
the BM of tumor-bearing mice. Finally, to confirm that lorlatinib
suppresses the tumor-induced expansion of neutrophils in the
BM, we isolated the BM from vehicle- or lorlatinib-treated tumor-
bearing mice and seeded the cells in a semi-solid methylcellulose
medium. We detected significantly fewer colonies in the plates
with BM cells from tumor-bearing lorlatinib-treated mice com-
pared to cells from vehicle-treated mice (Fig. 3k and S8i). Taken
together, these results suggest that lorlatinib suppresses the growth
of PDAC at both the primary tumor and at metastatic sites by
affecting neutrophils in three ways: (1) by modulating the devel-
opment of neutrophils in the BM, (2) reducing their accumulation
in the TME, and (3) by suppressing their ability to stimulate
growth of PDAC cells in the TME.
Lorlatinib extends survival of KPC mice. To test the efficacy of
lorlatinib in a spontaneous model of PDAC that recapitulates full
disease progression and the histopathological features of human
disease, we used the KPC mouse model. These mice have
pancreas-specific mutations in KrasG12D and Trp53R172H, and
develop invasive, metastatic tumors that exhibit an extensive
stroma with significant collagen deposition and infiltrating
immune cells48. KPC mice were treated with lorlatinib (5 mg/kg)
from 10 weeks of age (Fig. 4a). At this time, mice have widespread
advanced pancreatic neoplasia48 and are more likely to mimic
surgically resectable disease. Mice were monitored for signs of
disease and euthanized when they became symptomatic of disease
progression. We found that treatment with lorlatinib alone pro-
longed the survival of KPC mice with a median survival time of
172 days, compared to 150 days for control KPC mice (Fig. 4b).
Similar to our orthotopic and intrasplenic models, we found that
the primary tumors collected at end point (when mice show clear
symptoms of PDAC) from lorlatinib-treated KPC mice had
markedly reduced accumulation of Ly6G+ neutrophils by
immunofluorescence staining (Fig. 4c). We also confirmed that
lorlatinib treatment had markedly reduced levels of fibrosis, as
seen by both decreased collagen deposition and reduced numbers
of αSMA+ cells compared with untreated mice (Fig. 4d, e). While
we observed reduced metastatic burden in our liver metastasis
model, we did not observe any difference in metastatic burden in
lorlatinib-treated KPC mice. However, our results demonstrate
that lorlatinib treatment extends the survival of KPC mice, which
is associated with modulation of the pancreatic TME, similarly to
what we observed in the tumor transplantation models.
Lorlatinib improves anti-PD-1 therapy. Recent studies have
shown that modulation of TME components in PDAC can
improve the therapeutic response to chemotherapy or
immunotherapy6,49. To determine if lorlatinib could improve the
efficacy of chemotherapy, we treated mice bearing orthotopic
KPC tumors with gemcitabine (50 mg/kg) alone or in combina-
tion with lorlatinib (5 mg/kg) (Fig. 5a). Consistent with reported
results50, we found that treatment with gemcitabine had little
effect on the weight of orthotopic tumors. In contrast, similar to
our previous results, treatment with lorlatinib significantly
reduced the tumor weight (Fig. 5b). However, we did not observe
any further decrease in tumor weight when combining lorlatinib
with gemcitabine compared to lorlatinib alone (Fig. 5b). We
analyzed the immune cell composition of tumors from all treat-
ment groups by flow cytometry and found reduced neutrophil
accumulation in all treatment groups compared to the control
Fig. 3 Lorlatinib treatment suppresses neutrophil development. a Orthotopic implantation of KPC mT4 cells into the pancreas. Mice were treated daily
with combinations of vehicle (V), 5 mg/kg lorlatinib (L), 200 μg control IgG and anti-Ly6G. b Flow cytometry analysis of neutrophils in PDAC tumors from
mice treated with a combination of vehicle, lorlatinib, control IgG and anti-Ly6G (n= 9 mice, vehicle+ control IgG, and anti-Ly6G+ lorlatinib groups; n=
10 mice, remaining groups). c Tumor weight of orthotopic PDAC tumors from mice treated with a combination of vehicle, lorlatinib, control IgG, and anti-
Ly6G (n= 9 mice, vehicle+ control IgG; n= 10 mice, remaining conditions). Data are from two experiments. d Flow cytometry analysis of immune cells at
day 28 in blood samples from mice with PDAC tumors treated with vehicle or 5 mg/kg lorlatinib for 14 days (see outline of the experiment in Fig.1f) (n= 9
mice, vehicle; n= 10 mice, lorlatinib (monocytes/neutrophils); n= 10 mice per group (T cells); n= 6 mice per group (B cells); data are from two
independent experiments). e Flow cytometry analysis of immature (immNeu) and mature (matNeu) neutrophils in PDAC tumors at day 28 after treatment
with vehicle or lorlatinib for 14 days (n= 9 mice, vehicle; n= 10 mice, lorlatinib; data are from two independent experiments). f Flow cytometry analysis at
day 28 of GMPs, pre-neutrophils (preNeu), immature and mature neutrophils in the bone marrow (BM) from mice with PDAC tumors treated with vehicle
or lorlatinib for 14 days (n= 12 mice per group; data are from two independent experiments). g Colony-forming unit–granulocyte macrophage (CFU–GM)
assay of BM cells from healthy mice with vehicle or lorlatinib. Colonies with >20 cells were quantified after 3 days (n= 4 independent experiments).
h–j The number of colonies from CFU–GM (h) and flow cytometry analysis (g) of neutrophils on day 3 after CFU–GM culture in the (i) absence or (j)
presence of recombinant G-CSF and lorlatinib (n= 4 independent experiments). k CFU–GM of BM cells isolated on day 28 from mice with PDAC tumors
after daily treatment with vehicle or lorlatinib for 14 days (n= 4 mice per group). Scale bars represent 200 µm. Box-and-whisker plot shows the median
(line), mean (plus sign), 25th and 75th percentiles (box), and 5th and 95th percentiles (whiskers); hypothesis testing performed using two-way ANOVA
with Tukey’s (b, c, g, h) or Sidak’s (d–f, i, j) method for multiple comparisons or unpaired two-sided Student’s t test (k). Source data are provided as a
Source Data file.
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group (Supplementary Fig. 9a). We did not see any difference in
monocytes, macrophages, or CD8 T cells between any of the
treatment groups (Supplementary Fig. 9b–d). The reduction in
neutrophil accumulation was confirmed by IHC of tumor sec-
tions (Supplementary Fig. 9e). Finally, we analyzed proliferation,
fibrosis, and fibroblast accumulation in tumors from all treatment
groups by IHC and found no added benefit of adding gemcitabine
to lorlatinib compared to lorlatinib alone (Supplementary
Fig. 9f–h). These results support previous reports that gemcita-
bine treatment has little effect on PDAC and further suggest that
there is no additive effect of combining lorlatinib with gemcita-
bine in PDAC.
To determine if lorlatinib could improve the response to
immunotherapy in PDAC, we treated mice bearing orthotopic
KPC tumors with anti-PD-1 alone or in combination with
lorlatinib (5 mg/kg) (Fig. 5c). Consistent with previous reports51,
we found that treatment with anti-PD-1 had no effect on the
weight of orthotopic tumors compared to the control group
(control IgG+ vehicle). However, when combined with lorlatinib,
anti-PD-1 resulted in significantly smaller tumors compared to
tumors from the control group or single treatment groups
(Fig. 5d). We confirmed the reduced accumulation of neutrophils
in tumors from mice treated with lorlatinib alone or lorlatinib
combined with anti-PD-1 by both flow cytometry and IHC
staining of tumor sections (Fig. 5e, g). Interestingly, while
treatment with anti-PD-1 or lorlatinib alone was insufficient at
stimulating an increase in CD8+ T cells in tumors, combination
treatment with lorlatinib and anti-PD-1 significantly increased
the accumulation of CD8+ T cells as seen by both flow cytometry
and IHC staining (Fig. 5f, g). In addition, combination treatment
with lorlatinib and anti-PD-1 also resulted in more activated















































































Fig. 4 Lorlatinib treatment extends the survival of KPC mice. a KPC mice with spontaneous development of PDAC were treated daily with 5 mg/kg
lorlatinib starting when mice reached 10 weeks of age until they developed signs of disease progression. b Kaplan–Meier survival plot of KPC mice treated
from 10 weeks of age with lorlatinib (n= 25 mice) or untreated (n= 46 mice). Mice euthanized due to other pathologies are censored and cross-marked;
P value by log-rank test. c Representative immunofluorescence images and quantification of neutrophils (Ly6G+; purple) in PDAC tumors collected from
untreated or lorlatinib-treated KPC mice at the end of the experiment (n= 6 mice, untreated; n= 6 mice, lorlatinib; data are from one experiment). Five
FOV were acquired per mouse and used for quantification of Ly6G+ cells. d Representative picrosirius red staining and quantification of fibrosis in PDAC
tumors collected from untreated or lorlatinib-treated KPC mice at the end of the experiment (n= 6 mice, untreated; n= 7 mice, lorlatinib; data are from
one experiment). e Representative immunofluorescence images and quantification of fibroblasts (αSMA+; green) in PDAC tumors collected from
untreated or lorlatinib-treated KPC mice at the end of the experiment (n= 6 mice, untreated; n= 7 mice, lorlatinib; data are from one experiment). Scale
bars represent 250 µm (d) or 100 µm (c, e). Box-and-whisker plot shows the median (line), mean (plus sign), 25th and 75th percentiles (box), and 5th and
95th percentiles (whiskers); hypothesis testing performed using unpaired two-sided Student’s t test. Source data are provided as a Source Data file.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-23731-7 ARTICLE
NATURE COMMUNICATIONS |         (2021) 12:3414 | https://doi.org/10.1038/s41467-021-23731-7 | www.nature.com/naturecommunications 9
suggest that treatment with lorlatinib can make unresponsive
PDAC tumors responsive to immunotherapy with anti-PD-1
blockade.
Discussion
It is clear that improvements in treatment are urgently needed for
patients suffering from PDAC, which is characterized by a dismal
prognosis. PDAC tumors are characterized by a TME with
excessive deposition of ECM and infiltration of different immune
cells, which are believed to support tumor progression. At the
same time, the ability to modulate cells within the TME might
improve the therapeutic response of PDAC patients. In this study,
we find that treatment with lorlatinib suppresses tumor growth in


































































αPD-1 + LorlatinibIgG + Lorlatinib








































































































































































































































































αPD-1 + Vehicle IgG + Lorlatinib αPD-1 + LorlatinibIgG + Vehicle
18,24%0,99%0,67%0,60%
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growth of the primary tumor and metastases to the liver,
respectively, and suggest that lorlatinib primarily targets tumor-
associated neutrophils, since we did not observe any direct effect
of lorlatinib on pancreatic cancer cells or CAFs in vitro. However,
we cannot entirely exclude a direct in vivo effect of lorlatinib on
other intratumoral processes. Lorlatinib was also able to extend
the survival of a genetically engineered PDAC mouse model that
expresses mutant alleles of Kras and Tp53 and develop pancreatic
tumors whose pathophysiological and molecular features resem-
ble those of human PDAC. The results from these models indi-
cate that lorlatinib has a systemic effect, independent of the
tumor-affected organ since tumors in both the pancreas and
metastases in the liver demonstrated reduced fibrosis and limited
cancer cell proliferation.
Neutrophils have emerged as an influential component of the
TME in different cancer types15,52, including PDAC, but despite
recent advances in understanding neutrophil biology in cancer,
the mechanisms responsible for the pathological activation of
neutrophils are not well defined and this limits the selective
targeting of these cells. Lorlatinib was originally developed to
target ALK and several ALK inhibitors have already been
approved for the treatment of patients with ALK-positive
cancers53,54, including lorlatinib which was proven safe and tol-
erable in phase I and II trials25,55. While lorlatinib was designed
to primarily target ALK, it can also inhibit the activity of the non-
receptor tyrosine kinase FES26. In this study, we find that PDAC
cells activate FES signaling in neutrophils and that lorlatinib can
block this activation in vitro. Furthermore, we demonstrate that
lorlatinib reduces tumor-induced granulopoiesis and neutrophil
motility, which could have important implications for cancer
patients since recent results suggest that immature neutrophil
subsets, which are highly pro-tumorigenic, are produced in large
numbers, released from the BM and further recruited into the
TME46,56–58. It will be interesting to determine the precise role of
FES kinase in neutrophil biology in future studies. In mouse
models of PDAC, depletion of neutrophils using anti-Ly6G
antibodies or inhibition of CXCR2 signaling results in reduced
tumor growth, abrogation of metastasis, and improved influx of
cytotoxic T cells, which enables an improved checkpoint inhibi-
tion therapy response13,59,60. Interestingly, one study demon-
strated that neutrophil inhibition can lead to a compensatory
increase in other myeloid cells in PDAC tumors, such as
macrophages5, which has important implications when deciding a
treatment strategy for cancer patients. Our results suggest that
lorlatinib mainly affects neutrophils since we did not observe any
consistent differences in the accumulation of macrophages or
other immune cell types in our different models. Although, we
cannot formally exclude the possibility that lorlatinib directly
affects other immune cell types in our models in vivo. In contrast,
our data suggest that lorlatinib rather suppresses neutrophil
development in the BM and inhibits neutrophil-induced tumor
growth. In this context, lorlatinib could be used as a therapeutic
option to suppress the development and release of neutrophil
subsets in cancer patients. It is important to note the heterogeneity
of neutrophils in cancer, with no clear defining cell surface mar-
kers to distinguish tumor-associated neutrophils from myeloid-
derived suppressor cells, which are defined as immature with
highly immunosuppressive functions61. For that reason, we have
consistently used the term neutrophils to identify CD11b+Ly6C-
midLy6G+ cells, but it would be interesting to determine the
specific role of FES in regulating the functional phenotype of
neutrophils.
In addition, it could be a promising approach in the future to
validate the efficacy of lorlatinib in other cancer types with a high
degree of neutrophil recruitment since lorlatinib has already been
tested in humans, and approved for use in the clinic25,55.
In accordance with previous studies6,51, we did not observe any
effect of gemcitabine on tumor weight in our study, and the
combination of gemcitabine with lorlatinib did not enhance the
therapeutic effect of gemcitabine compared to lorlatinib alone.
However, one interesting aspect of that experiment is the obser-
vation that treatment with lorlatinib, but not gemcitabine, results
in reduced fibrosis and aSMA+ fibroblast accumulation. Simi-
larly, we observe reduced fibrosis and fibroblast accumulation in
the tumor after neutrophil depletion, similar to our observations
with lorlatinib treatment, but with no further reduction in fibrosis
after neutrophil depletion combined with lorlatinib. These
observations suggest that the reduction in fibrosis and activated
fibroblasts, potentially through neutrophil-fibroblast crosstalk,
may be an important mechanism by which lorlatinib reduces
tumor growth. Finally, while we did not see an improved tumor
response to the combination of lorlatinib and gemcitabine com-
pared with lorlatinib alone, we demonstrate that lorlatinib can
improve the therapeutic response to anti-PD-1 treatment leading
to reduced tumor size compared with lorlatinib or anti-PD-1
treatments alone and increased accumulation and activation of
CD8+ T cells, which would be important for PDAC patients. In
summary, we demonstrate that lorlatinib indirectly suppresses the
growth of PDAC at primary and metastatic sites by suppressing
neutrophil development in the BM and modulating tumor-
promoting neutrophil functions within the TME.
Methods
Animal studies. All experiments were carried out under authorization and gui-
dance from the Danish Inspectorate for Animal Experimentation and UK Home
Office license and approved by the University of Glasgow Animal Welfare and
Fig. 5 Lorlatinib treatment improves the response of PDAC tumors to immunotherapy, but not chemotherapy. a Orthotopic implantation of KPC mT4
cells into the pancreas. Mice were treated daily with vehicle (V) or 5 mg/kg lorlatinib (L) for 2 weeks and PBS or 50mg/kg gemcitabine twice per week
starting 14 days after implantation. b Weight of PDAC tumors from mice treated with vehicle or lorlatinib in combination with PBS or Gemcitabine (n= 8
mice per condition; data are from two independent experiments). c Orthotopic implantation of KPC mT4 cells into the pancreas. Mice were treated daily
with vehicle (V) or 5 mg/kg lorlatinib (L) for 2 weeks and 250 μg control IgG or anti-PD-1 antibodies three times per week starting 14 days after
implantation. d Weight of PDAC tumors from mice treated with combinations of vehicle, lorlatinib, control IgG, or anti-PD-1 (n= 12 mice per condition,
except n= 11 mice for control IgG+ lorlatinib condition; data are from three independent experiments). e, f Flow cytometry analysis of (e) neutrophils and
(f) CD8+ T cells in PDAC tumors from mice treated with combinations of anti-PD-1 and lorlatinib (n= 10 mice, control IgG+ vehicle; n= 11 mice, control
IgG+ lorlatinib; n= 12 mice, remaining groups; data are from three independent experiments). g Immunofluorescence analysis and quantification of
neutrophils (Ly6G+; purple) and T cells (CD8+; green) cells in PDAC tumors treated for 14 days with combinations of anti-PD-1 and lorlatinib (n= 10 mice,
control IgG+ vehicle and anti-PD-1+ vehicle groups, n= 9 mice for remaining groups; data are from two independent experiments). h Flow cytometry
plots and analysis of CD44+ CD69+ CD8+ T cells in tumors from mice treated with combinations of anti-PD-1 and lorlatinib (n= 10 mice, control IgG +
vehicle; n= 11 mice, control IgG+ lorlatinib; n= 12 mice, remaining groups; data are from three independent experiments). Scale bar represent 100 µm.
Box-and-whisker plot shows the median (line), mean (plus sign), 25th and 75th percentiles (box), and 5th and 95th percentiles (whiskers); hypothesis
testing performed using two-way ANOVA with Tukey’s method for multiple comparisons. Source data are provided as a Source Data file.
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Ethical Review Board. KrasLSL-G12D/+;Trp53LSL-R172H/+;Pdx1–Cre mice were
described previously48 and were bred in Glasgow on a mixed background. KPC
mice were monitored at least three times weekly and culled when exhibiting
symptoms of PDAC. Both male and female adult KPC mice were included in the
study. Female C57BL/6 mice (age 6–12 weeks; Taconic, Denmark) were used for
orthotopic or intrasplenic injections of KPC mT4 cells, whereas male C57BL/6
mice (6–12 weeks; Charles River, UK) were used for intrasplenic injections of
villinCreER Apcfl/flKrasG12D/+Trp53fl/R172HTgfbrIfl/fl organoids. Cohorts of mice
were randomized into different treatment groups before the start of treatment. At
least four mice were included per group for each experiment.
Tumor models and treatments
Orthotopic tumor model. Age-matched female C57BL/6 mice (6–12-weeks-old)
were used for the orthotopic mouse model. Orthotopic PDAC tumors were
established by surgical implantation. Briefly, 1 × 105 KPC mT4 cells in 20 µL
growth factor-reduced Matrigel were injected into each pancreas. Cohorts of mice
were randomized into different treatment groups by gross tumor diameter using
twice-weekly palpation. Tumor burden was measured by establishing the gross wet
weight of the pancreas.
Experimental liver metastasis model. Experimental liver metastasis was performed
by injecting 5 × 105 KPC mT4 or CRC cells in PBS into the spleen of immuno-
competent syngeneic female C57BL/6 mice using a Hamilton 29-G Syringe12. For
experimental colorectal cancer liver metastasis, single-cell suspensions were pre-
pared from villinCreER Apcfl/flKrasG12D/+Trp53fl/R172HTgfbrIfl/fl organoids before
injecting into the spleen of immunocompetent syngeneic male C57BL/6 mice. At
the indicated time points, mice were euthanized and metastatic tumor burden was
assessed by the weight of the liver relative to the whole mouse. We further assessed
the metastatic burden quantifying the frequency and size of metastatic lesions in
hematoxylin and eosin-stained paraffin-embedded liver sections by microscopy
using a Hamamatsu NanoZoom slide scanner and NDP.view2 software. The
metastatic index was calculated as the accumulated size of all metastatic lesions as a
percentage of the total area of the liver section.
Treatments. Lorlatinib was purchased from SelleckChem and dissolved in 2%
DMSO, 30% polyethyleneglycol 300, and 68% Hank’s balanced salt solution
(HBSS). Mice were given a daily oral administration of lorlatinib (5 mg/kg body
weight) or vehicle control using sterile 20-G feeding needles.
For neutrophil depletion, mice were treated with 200 μg/dose of InVivoMAb
anti-mouse Ly6G (clone 1A8; BioXCell, Cat # BP0075-1) or isotype control
antibody (clone 2A3, BioXcell, Cat # BP0089) diluted in InVivoPure pH 7.0
Dilution Buffer (BioXcell, Cat # IP0070) via intraperitoneal injections three times a
week for 2 weeks. Gemcitabine (Sigma, Cat # G6423) was dissolved in PBS, and
mice were treated with 50 mg/kg by intraperitoneal injection two times a week for
2 weeks. For anti-PD-1 treatment, mice were treated with 250 μg/dose of
InVivoMAb anti-mouse PD-1 (clone RMP1-14; BioXCell, Cat # BE0146) or isotype
control antibody (clone 2A3, BioXcell, Cat # BP0089) diluted in InVivoPure pH 7.0
Dilution Buffer (BioXcell, Cat # IP0070) via intraperitoneal injections three times a
week for 2 weeks.
Cell culture. Murine pancreatic cancer cells KPC mT4, generated in the Tuveson
Laboratory (Cold Spring Harbor Laboratory, NY, USA), were isolated from PDAC
tumor tissues obtained from KrasLSL-G12D/+;Trp53LSL-R172H/+;Pdx1–Cre mice of a
pure C57BL/6 background62. KPC mT4 cells were cultured in DMEM+ 10% FBS
and supplemented with 100 units of penicillin and 100 µgml−1 streptomycin. For
some experiments, we used KPC mT4 cells that were engineered to express the
fluorescent protein zsGreen and Firefly Luciferase. These cells were generated by
lentiviral particle infection with pHIV Luc–zsGreen (gift from B. Welm, University
of Utah, USA, Addgene plasmid no. 39196). Cells were sorted by flow cytometry for
high zsGreen expression levels. CAF cell lines 17964-56 and 19238-43, generated in
the Tuveson laboratory42 (Cold Spring Harbor Laboratory, NY, USA), were isolated
from PDAC tumor tissues obtained from KrasLSL-G12D/+;Trp53LSL-R172H/+;
Pdx1–Cremice and cultured in DMEM+ 5% FBS and supplemented with 100 units
of penicillin and 100 µgml−1 streptomycin. Murine colorectal cancer cells were
generated from tumors in villinCreER Apcfl/fl KrasG12D/+ Trp53fl/R172H TgfbrIfl/fl
mice41 and cultured as organoids in Matrigel (BD Biosciences, 356231) with
Advanced DMEM/F12 supplemented with penicillin/streptomycin (100 U/ml / 100
µg/ml) (15140122), 2 mM L-glutamine (25030081), 10 mM HEPES (15630080), N2-
supplement (17502001), and B27-supplement (17504044) (all ordered from Gibco,
Life Technologies, ThermoFisher Scientific, Paisley, UK), 50 ng/ml Recombinant
Human EGF (AF-100-15, Peprotech, London, UK), 100 ng/ml Recombinant Mur-
ine Noggin (250-38, Peprotech). All cells were cultured at 37 °C, 5% CO2 in a
humidified chamber. All cell lines were routinely tested negative for mycoplasma
and tested negative for murine pathogens by IMPACT testing (IDEXX Laboratories,
USA). None of the cell lines used in this manuscript are listed in the ICLAC and
NCBI Biosample database of misidentified cell lines.
Neutrophil isolation and purification. Primary murine neutrophils were isolated
by flushing the BM from the femur and tibia of C57BL/6 mice followed by double
density-gradient centrifugation on histopaque (1077 and 1119 g/mL) (Sigma, 10771
and 11191) at 300×g for 25 min (without brakes). All cells were collected from the
two interfaces and further purified using the Neutrophil Isolation Kit (Miltenyi)
according to the manufacturer’s instructions. The purity of isolated neutrophils was
determined by flow cytometry using anti-CD45, anti-Ly6G, and anti-CD11b
antibodies.
Conditioned medium preparation and cytokine array. Conditioned medium
from KPC mT4 cells was generated according to the previous reports63. The
medium was removed from 70% confluent KPC mT4 cells and cells were washed
three times with PBS before the addition of serum-free medium. Cells were
incubated for 18–24 h in serum-free medium and then collected and filtered
through 0.45-µm filters before immediate use.
Cytokine array was performed using Proteome Profiler Mouse Cytokine Array
Kit, Panel A (R&D, #ARY006) according to the manufacturer’s instruction. The
membranes were developed for 10 min. Data acquisition was performed using an
ImageQuantTM LAS 400 instrument and images were analyzed using ImageJ.
Kinase profiling. The neutrophil cell lysate was prepared by lysis with Mammalian
Protein Extraction Reagent (M-PERTM) containing HaltTM Phosphatase Inhibitor
Cocktail (1:100) and HaltTM Protease Inhibitor Cocktail (1:100) for 30min at 4 °C
on a rocker. Cell extracts were cleared by centrifugation for 10min at 16,000×g at
4 °C, and protein concentrations were determined by Bradford assays (Pierce).
Aliquots of 1 mg/ml were prepared and snap-frozen in liquid nitrogen. Measure-
ments were performed on a PamChip Kinase Profiling Microarray System (Pam-
Station 12, PamGene)27. Briefly, 5 µg of protein extract was used for the PTK array
protocol (V1.9) using chips containing peptides (with known phosphorylation sites)
immobilized in an array format on a porous membrane. The PTK array was pro-
cessed in a single-step reaction. Cell extracts, ATP, and fluorescein isothiocyanate
(FITC)-labeled pY20 antibody were incubated on the chip, and the phosphorylation
of the individual Tyr peptides was followed by fluorescence detection in real time.
Development of the FITC fluorescence signal was detected. Signal intensities were
analyzed in BioNavigator software (PamGene) and expressed as log fold change.
Prediction of kinases responsible for altered phosphorylation between conditions
was analyzed using the upstream kinase analysis app (2018 version; PamGene) and
was based on multiple kinase–substrate relationship databases. A full list of pre-
dicted kinases is supplied in Supplementary Data Files 1–5.
Transwell migration. To evaluate neutrophil chemotaxis, KPC-conditioned
medium or individual recombinant cytokines/chemokines were added to the lower
well of a 24-well plate and freshly isolated neutrophils were seeded into the upper
chamber of the insert on a 3-µm porous membrane. After 2 h, inserts were
removed, and the inside was swabbed thoroughly with cotton tips and then fixed in
methanol containing 0.05% crystal violet. The number of migrated neutrophils was
counted by bright-field microscopy and presented as the number of cells/field of
view or calculated relative to the control using the formula: (number of migrated
neutrophils in treatment/ number of migrated neutrophils in control) × 100.
CAF contraction. To assess force‐mediated matrix contraction, CAFs (derived
from pancreatic tumors in the KPC mouse model:42 19238 or 17564: 8 × 104 cells)
were embedded in 100 μl collagen I at a concentration of ~4 mg/ml and seeded in
96‐well plates64. Once the gel was set (1 h), cells were washed once in normal media
for 1 h and then replaced with fresh media with or without lorlatinib. Gel con-
traction was monitored after 72 h by taking photographs of the gels. To obtain the
gel contraction value, the relative diameters of the well and the gel were measured
using ImageJ software, and the percentage of contraction was calculated using the
formula 100 × (well diameter− gel diameter)/well diameter.
Bone marrow colony formation. Colony-formation assays were performed
according to the manufacturer’s protocol (StemCell Technologies). Briefly, cells
were isolated from the BM, as described above, and were cultured in duplicate
(30.000 cells per plate) in methylcellulose-based medium (MethoCult #3534;
StemCell Technologies) containing recombinant cytokines (SCF, IL-3, and IL-6) in
the presence of lorlatinib or DMSO for 3 days. After 3 days of incubation at 37 °C,
the dishes were photographed, and the total colony numbers and types of colonies
in plates were evaluated under a microscope, and colonies with >20 cells were
scored.
Proliferation and viability
Cancer cell and fibroblast proliferation. KPC mT4 cells or fibroblasts were seeded at
a concentration of 2000 cells per well in a 96-well plate and allowed to adhere
overnight. The next day, fresh cell culture medium was added to the cells sup-
plemented with lorlatinib (1 or 10 µM) or vehicle control (DMSO). The cells were
cultured for 2 days, and growth was measured by adding 20 µl CellTiter96 AQueous
One Solution Reagent to the cells. After 1 h at 37 °C in a humidified 5% CO2
atmosphere, the absorbance at 490 nm was recorded using an ELISA plate reader.
The same measurement was performed immediately after the cell culture medium
change to measure day 0.
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Neutrophil viability. Neutrophils were prepared fresh from the BM of healthy mice
as described in the methods and seeded at a concentration of 100.000 cells per well
in poly-L-lysine-coated 96-well plates. Cells were allowed to attach for 1 h before
the addition of DMEM (+ 5% FBS) supplemented with either 10 ng/mL GM-CSF
or 40 ng/mL G-CSF, or KPC-CM (+ 5% FBS). Lorlatinib was added to final
concentrations of 1 and 10 μM. DMSO was used as vehicle control at a 0.01% vol.
Cells were cultured for two days and viability measured by adding CellTiter-Glo
according to the manufacturer’s instructions and measuring the luminescence
using an ELISA plate reader. The luminescence signal was normalized to the
measurement of cells on day 0 (after seeding).
Neutrophil-KPC co-cultures. For neutrophil-induced proliferation of KPC mT4-
Luc/zsGreen cells, neutrophils were isolated from the BM of healthy, tumor-free
mice as described in the “Methods” and seeded (600.000 cells per well) in poly-L-
lysine (10 µg/mL)-coated tissue culture plates in the presence of KPC-CM and
vehicle or lorlatinib. A small number of KPC mT4-Luc/zsGreen cells (2.000 per
well) were seeded in the chamber alone or together with the neutrophils and
cultured for 2 days. Cells were fixed with 4% PFA, permeabilized with 0.5% Triton
X-100, and stained with DAPI to quantify the number of zsGreen+ KPC mT4 cells
in the co-cultures.
Immunoblots. Cell lysates were prepared from neutrophils stimulated with serum-
free medium or KPC-CM in the presence or absence of 10 µM lorlatinib with M-
PERTM Mammalian Extraction Buffer containing HaltTM Phosphatase Inhibitor
Cocktail (1:100) and HaltTM Protease Inhibitor Cocktail, EDTA (1:100). Protein
lysates were resolved on NuPAGE 4–12% Bis-Tris gels (ThermoFisher Scientific,
#17080971) and transferred to nitrocellulose membranes. Membranes were blocked
in 5% milk for 1 h and incubated with primary antibodies overnight at 4 °C. The
next day, membranes were washed with PBS+ 0,1% Tween20 and incubated with
appropriate HRP-conjugated secondary antibodies for 1 h. Immunoblots were
visualized on an ImageQuantTM LAS 400 instrument and images were analyzed
using ImageJ. Vinculin or α-tubulin were used as sample integrity controls on
separate blots (Supplementary Fig. 2). A list of the antibodies used for immuno-
blots in this paper can be found in Supplementary Table 2.
Quantitative RT-PCR. Cells were lysed by either directly sorting them by FACS
directly into RLT lysis buffer (containing β-mercaptoethanol) or direct lysis in their
cell culture vessel. RNA was extracted using the RNeasy Mini Kit (Qiagen) fol-
lowing the manufacturer’s instructions. RNA concentration was measured using a
NanoDrop. Reverse transcription of 500 ng of RNA was performed using iScript
cDNA Synthesis Kit (BioRad) following the manufacturer’s instructions. Primers
corresponding to mouse ribosomal protein lateral stalk subunit P0 (Rplp0) (for-
ward: CATCATCAATGGGTACAAGCGC, reverse: CAGTAAGTGGGAAGGTGT
ACTC), Acta2 (forward: ATCACCATCGGAAATGAACG; reverse: CTGGAAGG
TGGACAGAGAGG), Col1a (forward: CGATGGATTCCCGTTCGAGT; reverse:
GAGGCCTCGGTGGACATTAG) or Fes (Qiagen; Mm_Fes_1_SG QuantiTect
Primer Assay). Quantitative RT-PCR was performed on a LightCycler 480 II
(Roche). Relative expression levels were normalized to Rplp0 expression according
to the formula 2−(CT for gene of interest − CT Rplp0).
Immunostaining of frozen or paraffin-embedded tissue sections
Frozen tissue sections. Murine liver tissues were embedded in Optimal Cutting
Temperature (OCT) medium and stored at −80 °C. Tissue sections were fixed in
4% paraformaldehyde, permeabilized with PBS+ 0.1% Triton X-100, blocked with
PBS+ 8% normal goat serum, and incubated with primary antibodies. Next, tissue
sections were washed in PBS, stained with secondary antibodies including DAPI
(Life Technologies, 1 µg/ml), and mounted using Dako Fluorescent Mounting
Medium. Goat anti-rat or goat anti-rabbit secondary antibodies conjugated to
AlexaFluor488 and AlexaFluor555 were used (Abcam, 1:500). Antibodies used for
immunostainings of tissue sections are listed in Supplementary Table 2. All tissue
sections were imaged using a Leica SP8 confocal microscope and quantified using
ImageJ software.
Immunohistochemistry of paraffin-embedded tissue slides. Mouse tumors were
resected, fixed in 10% neutral buffered formalin overnight at 4 °C, and paraffin-
embedded according to the standard protocol. Five-micrometer sections were
processed for hematoxylin and eosin (H&E) per standard protocol. For immu-
nohistochemistry staining, tissue sections were first deparaffinized in xylene and
rehydrated in graded ethanols. Antigen retrieval was performed for 10 min at
95–98 °C in 10 mM sodium citrate buffer, pH 6.0, or 1 mM EDTA, pH 8.0. Then,
endogenous peroxidase activity was quenched by 3% H2O2 for 10 min. Sections
were blocked in T-PBS containing 0.1% Triton X-100 (Sigma) and 5% goat or
donkey serum. Incubations with primary antibodies were performed overnight at 4
°C in a humidified chamber, followed with appropriate HRP-conjugated secondary
antibodies (Dako, K4001, or K4003) at room temperature. ImmPACT DAB Kit
(Vector Laboratories, SK-4105) was used to develop signals per the manufacturer’s
instructions. Sections were counterstained with hematoxylin and mounted using
DPX mounting medium (CellPath, SEA-1304-00A). Multiplex immuno-
fluorescence staining of tumor slides was carried out similarly to
immunohistochemistry staining, except that sections were blocked in PBS con-
taining 0.1% Tween20, 5% goat serum, and subsequently incubated with primary
antibodies overnight. The next day, slides were washed and incubated with Alexa
Fluor-conjugated secondary antibodies including DAPI (1 µg/ml) for 1 h at room
temperature and mounted using Dako Fluorescent Mounting Medium. Antibodies
used for immunostainings of tissue sections are listed in Supplementary Table 2.
Flow cytometry. Single-cell suspensions from murine tumors or hepatic metas-
tases were prepared by mechanical and enzymatic disruption in Hanks balanced
salt solution (HBSS) with 1 mgml−1 collagenase P (Roche) using the mTDK1
program on a gentleMACS™ Dissociator (Miltenyi Biotec). Briefly, cells in sus-
pension were centrifuged for 5 min at 1200 r.p.m., resuspended in HBSS, and
filtered through a 500-µm polypropylene mesh (Spectrum Laboratories). The cell
suspension was resuspended in 1 ml 0.05% trypsin and incubated at 37 °C for
5 min. Cells were filtered through a 70-µm cell strainer and resuspended in PBS+
1% BSA. Cells were blocked for 10 min on ice with FC Block (BD Pharmingen,
Clone 2.4G2) and then stained with Sytox viability marker (Life Technologies) and
fluorochrome-conjugated antibodies.
BM was prepared by flushing the femur and tibia from both hind legs of
euthanized mice. Hematopoietic lineage discrimination of BM samples was
performed using fluorochrome-conjugated antibodies. Blood was harvested from
euthanized mice by cardiac puncture using EDTA-coated syringes and 25-G
needles. Red blood cells were lysed using BD Pharm Lyse (BD Biosciences, 555899).
Flow cytometry was performed on a FACSAria III (BD Biosciences). All antibodies
used for flow cytometry are listed in Supplementary Table 1.
Quantification of absolute numbers of cells per tissue using fluorescent
beads. CountBright beads (CountBright Absolute Counting Beads; Invitrogen)
were added to each single-cell suspension stained for flow cytometry. At least 1000
beads were acquired per tube to ensure accuracy for estimation of an absolute
number of cells. For tumor and BM, the absolute number of cells is presented as
cells per tumor or BM (tibia and femur from both hind legs).
Statistical analysis. For studies comparing differences between two groups, we
used unpaired Student’s t tests. For the Kaplan–Meier survival study we used the
log-rank test. For studies comparing more than two groups, we used ANOVA with
appropriate post hoc testing. Differences were considered significant when P < 0.05.
Data are presented as box-and-whisker plots showing the median (line), mean
(plus sign), 25th and 75th percentiles (box), and 5th and 95th percentiles (whis-
kers) or as bar graphs showing mean ± standard deviation.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The transcriptome data used in this study are available in the GEO database under
accession code: GSE109467 (bulk RNAseq from murine bone marrow neutrophil
subsets) or BloodSpot database (http://servers.binf.ku.dk/bloodspot) with HemaExplorer
dataset (bulk RNAseq from human bone marrow subsets). A full list of the predicted
kinase activity including the detected level of phosphorylation for each bait peptide is
provided as Supplementary Data 1–5. The remaining data are available within the
Article, Supplementary Information, or available from the authors upon reasonable
request. Source data are provided with this paper.
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